Professional Profile

Medical School, Free University of Berlin, Berlin, Germany, and University of London, London, England

Dr. med. (research doctorate), Free University of Berlin, Berlin, Germany

Postdoctoral Fellow, Department of Cell Biology, Baylor College of Medicine, Houston, Texas

Habilitation in Pharmacology and Toxicology, University of Zurich, Zürich, Switzerland

Medical Specialist in Pharmacology and Toxicology, Chamber of Physicians, Berlin, Germany

Director of the Laboratory of Genetic Neuropharmacology at McLean Hospital, Belmont, Mass., and Lecturer, Associate Professor, and Full Professor at Harvard Medical School, Boston, Mass.

External Lecturer of Pharmacology and Toxicology, Swiss Federal Institute of Technology (ETH), Zürich, Switzerland

Senior Scientist, Lecturer and Assistant Professor of Molecular Neuropharmacology, Institute of Pharmacology and Toxicology, University of Zurich Medical School, Zürich, Switzerland

Instructor, Department of Cell Biology, Baylor College of Medicine, Houston, Texas

Early in his career, Dr. Rudolph pursued biochemical studies on G-protein-mediated signal transduction and generated the first G-protein knockout mouse, which developed ulcerative colitis and adenocarcinoma of the colon. He then applied genetic tools to the analysis of inhibitory neurontransmission in the brain, showing for example that benzodiazepine-induced anxiolysis and sedation are pharmacologically separable, and that commonly used general anesthetics exert their immobilizing action via a specific receptor subtype. Recent studies established circuit-dependent pharmacological functions of GABA_A receptors (“circuit pharmacology”), the targets of benzodiazepine drugs. He also contributed to a recent study demonstrating itch suppression in mice and dogs by modulation of spinal GABA_A receptors.

See Dr. Rudolph's publications in PubMed.